Usually when a licensed firm like Taglich Brothers, Inc. announces that it initiated coverage on your penny stock, you see a surge in volume. That hasn’t happened yet for OxySure Systems, Inc. (OXYS) even though the company pioneered a safe and easy to use solution to produce medically pure (USP) oxygen from inert powders. Considering the company has already surpassed their robust sales numbers for all of 2012 and owns 9 issued patents and patents pending on their technology which makes the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen provision systems, OXYS stock is bound to breathe some serious life into accounts in one-one thousand, two-one thousand, three-one thousand…
Our Next Pick Is Coming Soon! Click HERE To Make Sure You Don’t Miss Any Of Our Breaking Alerts!
OXYS Stock Quote
Market Cap: 16.84M
Monday Close: 0.729 ▲ +0.089 (+13.91%)
Volume: 7,800
Open: 0.64
High: 0.732
Low: 0.64
Trades: 11
Authorized: 100,000,000
Issued and Outstanding: 23,103,996
1st Resistance Point: 0.7607
1st Support Level: 0.6687
Looking for Hot Penny Stocks?
Click here To Receive FREE Penny Stock Alerts
It’s only a matter of time before volume picks up on OxySure Systems’ OXYS stock, especially when word gets out on how small the float is and who they appointed to their Board of Directors effective April 1 – none other than the former Chairman and CEO of Apria Healthcare, Jeremy M. Jones (aka Jerry Jones).
Like what the one Jerry Jones did when he took over the reigns at the Dallas Cowboys to make them Champions, OxySure’s Jerry Jones has over 3 decades of healthcare industry experience having founded Homedco Group, Inc., a home healthcare services company which he took public in 1991 and later merged into Apria Healthcare Group, Inc. in 1995. While CEO and Chairman of Apria, which became the largest homecare service provider in the nation under his leadership, Jones made a flurry of moves to increase the company’s market dominance before selling out to the Blackstone Group (NYSE: BX) for $1.7 billion in December 1998.
Currently serving as Chairman of On Assignment, Inc. (NYSE: ASGN), a $1.3 billion leader in the healthcare and life sciences sectors focusing on in-demand, skilled medical and technical staffing, having his presence at OxySure Systems is a win-win scenario for anyone intelligent enough to act on the appointment and be able to sit and wait on OXYS stock.
It’s likely that, with the proven success of OxySure’s products and how they improve access to emergency oxygen that affects the survival, recovery and safety of individuals in several areas of need, the company’s Model 615 could one day become as staple of an item as the fire extinguisher. The market is huge for OxySure’s Model 615 which includes:
(1) Public and private places and settings where medical emergencies can occur;
(2) Individuals at risk for cardiac, respiratory or general medical distress needing immediate help prior to emergency medical care arrival; and
(3) Those requiring immediate protection and escape from exposure situations or oxygen-deficient situations in industrial, mining, military, or other “Immediately Dangerous to Life or Health” environments
As far as money flow goes, OxySure reported revenues of $269,697 for all of 2012 versus $185,209 for all of 2011, an increase of $84,488 (46%). They just about surpassed all of 2012 numbers in Q1 alone when they reported revenues of $240,420 for the 3 months ended March 31, 2013. Add the growth together with the appointment of Jerry Jones and then divide it by the fact that Julian T. Ross, CEO, President, and CFO of OxySure, owned 16,870,285 shares of OXYS stock as of December 31, 2012, and what you have is an immediate runner once traders take note of it like Taglich Brothers just over a week ago.
There were some significant stock transactions during he course of 2012 which any investor considering to buy OXYS stock should know of:
(1) 1,711,952 shares were issued pursuant to the conversion of convertible subordinated promissory notes totaling $2,433,850 at an aggregate conversion price of $1.42 per share;
(2) 2,815,374 shares were issued pursuant to the cashless conversion of 2,307,684 shares of our Series A Preferred at a conversion ratio of 1.22:1;
(3) 374,808 shares were issued pursuant to the exercise of 374,808 stock options for $98,284;
(4) 882,616 shares were issued pursuant to the exercise of 882,616 warrants for $6,106;
(5) 68,889 shares were issued for $41,250 in cash at an aggregate price of $.60 per share;
(6) 97,500 shares were issued for services valued at approximately $20,748; and
(7) 77,674 shares were issued in connection with the acquisition of assets valued at approximately $95,062
So, from $1.42 on note conversions to 0.0069 on exercised warrants, the cost basis for some of the OXYS shares in play make up a broad range of where the PPS could eventually wind up. For those thinking the lower end of the spectrum, they are likely going to miss out on what should be an easy triple-bagger from 0.73.
About OXYS Stock
OxySure Systems, Inc. is a medical technology company that focuses on the design, manufacture and distribution of specialty respiratory and emergency medical solutions.
Click here to view the SEC filings for OXYS.
Click here to view the website for OxySure.
Last 5 Trading Sessions:
| Date | Last | Change | Volume | |
| 08/01/13 | 0.6400 | -0.0100 | -1.54% | 12,600 |
| 07/31/13 | 0.6500 | -0.0200 | -2.99% | 1,300 |
| 07/30/13 | 0.6700 | unch | unch | 200 |
| 07/29/13 | 0.6700 | +0.0100 | +1.52% | 12,500 |
| 07/26/13 | 0.6600 | +0.0100 | +1.54% | 8,200 |
Stay Connected With Us:
Bottom Line:
Only the traders who are focused on playing pumped penny stocks will miss out on any action that will occur on OXYS stock. As real as real gets, OXYS deserves one of the top spots on your immediate watchlist. Q2 numbers will be coming out any day now and the growth in sales is due to trigger a colossal trading session whereby accumulation is likely to be the main driver that sends the PPS over and above $1+ with ease.
Here is your opportunity to subscribe to the Most Read Penny Stock Newsletter
If You Can’t Make Money With Us, You Shouldn’t Be Trading Penny Stocks
(We are 100% Anti-Spam and will never rent or sell your information)
ShareAUG
